View in EDS HTML Full Text PDF Full Text

A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration.

Saved in:
Bibliographic Details
Title: A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea® in Patients with Wet Age-Related Macular Degeneration.
Authors: Bansal, Mudit1 (AUTHOR), Singh, Punit2 (AUTHOR), Mehta, Ruchi K.3 (AUTHOR), Laul, Rohit Sanjay4 (AUTHOR), Rana, Parth5 (AUTHOR), Shah, Urmil6 (AUTHOR), Vohra, Rajpal7 (AUTHOR), Desai, Shachi8 (AUTHOR), Bhomaj, Sharad9 (AUTHOR), Patwardhan, Sourabh10 (AUTHOR), Manoher, Jaishri Murli11 (AUTHOR), Sapar, Anjali12 (AUTHOR), Parwal, Sandeep13 (AUTHOR), Amabde, Ajay Kartik14 (AUTHOR), Shroff, Rahul15 (AUTHOR), Natesh, Sribhargava16 (AUTHOR), Biswas, Rupak Kanti17 (AUTHOR), D, Lional Raj18 (AUTHOR), Sinha, Bibhuti P.19 (AUTHOR), C K, Minija20 (AUTHOR)
Source: Ophthalmology & Therapy. Feb2026, Vol. 15 Issue 2, p803-816. 14p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938245
DOI:10.1007/s40123-025-01299-5